Search

Your search keyword '"Pijnappel R"' showing total 175 results
Start Over Author "Pijnappel R"
175 results on '"Pijnappel R"'

2. Mammographic screening detects low-risk tumor biology breast cancers.

Author

van Leeuwen, F, Pijnappel, R, Slaets, L, Bogaerts, J, Vant Veer, L, Drukker, C, Schmidt, M, Rutgers, E, Cardoso, F, Esserman, Laura, and Kerlikowske, Karla

Subjects
Aged, Breast Neoplasms, Early Detection of Cancer, Female, Humans, Mammography, Middle Aged, Risk, Transcriptome
Abstract

Overdiagnosis of breast cancer, i.e. the detection of slow-growing tumors that would never have caused symptoms or death, became more prevalent with the implementation of population-based screening. Only rough estimates have been made of the proportion of patients that are overdiagnosed and identification of those patients is difficult. Therefore, the aim of this study is to evaluate whether tumor biology can help identify patients with screen-detected tumors at such a low risk of recurrence that they are likely to be overdiagnosed. Furthermore, we wish to evaluate the impact of the transition from film-screen mammography (FSM) to the more sensitive full-field digital mammography (FFDM) on the biology of the tumors detected by each screening-modality. All Dutch breast cancer patients enrolled in the MINDACT trial (EORTC-10041) accrued 2007-2011, who participated in the national screening program (biennial screening ages 50-75) were included (n = 1,165). We calculated the proportions of high-, low- and among those the ultralow-risk tumors according to the 70-gene signature for patients with screen-detected (n = 775) and interval (n = 390) cancers for FSM and FFDM. Screen-detected cancers had significantly more often a low-risk tumor biology (68 %) of which 54 % even an ultralow-risk compared to interval cancers (53 % low-, of which 45 % ultralow-risk (p = 0.001) with an OR of 2.33 (p < 0.0001; 95 % CI 1.73-3.15). FFDM detected significantly more high-risk tumors (35 %) compared to FSM (27 %) (p = 0.011). Aside from favorable clinico-pathological factors, screen-detected cancers were also more likely to have a biologically low-risk or even ultralow-risk tumor. Especially for patients with screen-detected cancers the use of tools, such as the 70-gene signature, to differentiate breast cancers by risk of recurrence may minimize overtreatment. The recent transition in screening-modalities led to an increase in the detection of biologically high-risk cancers using FFDM.

Published
2014

4. The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results

Author

Young-Afat, D. A., van Gils, C. H., van den Bongard, H. J. G. D., Verkooijen, H. M., Gernaat, S. A., Gregorowitsch, M. L., May, A. M., Peeters, P. H., van der Pol, C. C., Witkamp, A. J., Pijnappel, R. M., Bijlsma, R. M., Maarse, W., Ausems, M. G., van Diest, P. J., van der Wall, E., van Dalen, T., Burgmans, I. P., de Roos, M. A., van Doorn, R. C., Baas, I. O., van Ooijen, B., Koelemij, R., and on behalf of the UMBRELLA Study Group

Published
2017
Full Text
View/download PDF

7. Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA

Author

Beeldverwerking ISI, Cancer, Trialbureau Beeld, Medisch Oncologische Disciplines, Speerpunt Cancer, Team Smart 1, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Radiologie, Epi Kanker Team C, Ragusi, M.A.A., van der Velden, B.H.M., van Maaren, M.C., van der Wall, E., van Gils, C. H., Pijnappel, R. M., Gilhuijs, K.G.A., Elias, S.G., Beeldverwerking ISI, Cancer, Trialbureau Beeld, Medisch Oncologische Disciplines, Speerpunt Cancer, Team Smart 1, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Radiologie, Epi Kanker Team C, Ragusi, M.A.A., van der Velden, B.H.M., van Maaren, M.C., van der Wall, E., van Gils, C. H., Pijnappel, R. M., Gilhuijs, K.G.A., and Elias, S.G.

Published
2022

11. OC-0067 De-escalation of radiation therapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM)

Author

de Wild, S., primary, de Munck, L., additional, Verloop, J., additional, van Dalen, T., additional, Elkhuizen, P., additional, Houben, R., additional, van Leeuwen, E., additional, Linn, S., additional, Pijnappel, R., additional, Poortmans, P., additional, Strobbe, L., additional, Wesseling, J., additional, Voogd, A., additional, and Boersma, L., additional

Published
2021
Full Text
View/download PDF

12. How does image quality affect radiologists' perceived ability for image interpretation and lesion detection in digital mammography?

Author

Boita, J.M., Engen, R.E. van, Mackenzie, A., Tingberg, A., Bosmans, H., Bolejko, A., Zackrisson, S., Wallis, M.G., Ikeda, D.M., Ongeval, C. Van, Pijnappel, R., Broeders, M.J.M., Sechopoulos, I., Boita, J.M., Engen, R.E. van, Mackenzie, A., Tingberg, A., Bosmans, H., Bolejko, A., Zackrisson, S., Wallis, M.G., Ikeda, D.M., Ongeval, C. Van, Pijnappel, R., Broeders, M.J.M., and Sechopoulos, I.

Abstract

Contains fulltext : 235766.pdf (Publisher’s version ) (Open Access), OBJECTIVES: To study how radiologists' perceived ability to interpret digital mammography (DM) images is affected by decreases in image quality. METHODS: One view from 45 DM cases (including 30 cancers) was degraded to six levels each of two acquisition-related issues (lower spatial resolution and increased quantum noise) and three post-processing-related issues (lower and higher contrast and increased correlated noise) seen during clinical evaluation of DM systems. The images were shown to fifteen breast screening radiologists from five countries. Aware of lesion location, the radiologists selected the most-degraded mammogram (indexed from 1 (reference) to 7 (most degraded)) they still felt was acceptable for interpretation. The median selected index, per degradation type, was calculated separately for calcification and soft tissue (including normal) cases. Using the two-sided, non-parametric Mann-Whitney test, the median indices for each case and degradation type were compared. RESULTS: Radiologists were not tolerant to increases (medians: 1.5 (calcifications) and 2 (soft tissue)) or decreases (median: 2, for both types) in contrast, but were more tolerant to correlated noise (median: 3, for both types). Increases in quantum noise were tolerated more for calcifications than for soft tissue cases (medians: 3 vs. 4, p = 0.02). Spatial resolution losses were considered less acceptable for calcification detection than for soft tissue cases (medians: 3.5 vs. 5, p = 0.001). CONCLUSIONS: Perceived ability of radiologists for image interpretation in DM was affected not only by image acquisition-related issues but also by image post-processing issues, and some of those issues affected calcification cases more than soft tissue cases. KEY POINTS: * Lower spatial resolution and increased quantum noise affected the radiologists' perceived ability to interpret calcification cases more than soft tissue lesion or normal cases. * Post-acquisition image processing-related effects

Published
2021

13. Development and content validity evaluation of a candidate instrument to assess image quality in digital mammography: A mixed-method study

Author

Boita, J.M., Bolejko, A., Zackrisson, S., Wallis, M.G., Ikeda, D.M., Ongeval, C. Van, Engen, R.E. van, Mackenzie, A., Tingberg, A., Bosmans, H., Pijnappel, R., Sechopoulos, I., Broeders, M.J.M., Boita, J.M., Bolejko, A., Zackrisson, S., Wallis, M.G., Ikeda, D.M., Ongeval, C. Van, Engen, R.E. van, Mackenzie, A., Tingberg, A., Bosmans, H., Pijnappel, R., Sechopoulos, I., and Broeders, M.J.M.

Abstract

Contains fulltext : 229548.pdf (publisher's version ) (Open Access), PURPOSE: To develop a candidate instrument to assess image quality in digital mammography, by identifying clinically relevant features in images that are affected by lower image quality. METHODS: Interviews with fifteen expert breast radiologists from five countries were conducted and analysed by using adapted directed content analysis. During these interviews, 45 mammographic cases, containing 44 lesions (30 cancers, 14 benign findings), and 5 normal cases, were shown with varying image quality. The interviews were performed to identify the structures from breast tissue and lesions relevant for image interpretation, and to investigate how image quality affected the visibility of those structures. The interview findings were used to develop tentative items, which were evaluated in terms of wording, understandability, and ambiguity with expert breast radiologists. The relevance of the tentative items was evaluated using the content validity index (CVI) and modified kappa index (k*). RESULTS: Twelve content areas, representing the content of image quality in digital mammography, emerged from the interviews and were converted into 29 tentative items. Fourteen of these items demonstrated excellent CVI>/=0.78 (k* > 0.74), one showed good CVI<0.78 (0.60

Published
2021

15. Trends in delayed breast cancer diagnosis after recall at screening mammography

Author

MS Radiologie, Cancer, Lameijer, J R C, Voogd, A C, Broeders, M J M, Pijnappel, R M, Setz-Pels, W, Strobbe, L J, Jansen, F H, Tjan-Heijnen, V C G, Duijm, L E M, MS Radiologie, Cancer, Lameijer, J R C, Voogd, A C, Broeders, M J M, Pijnappel, R M, Setz-Pels, W, Strobbe, L J, Jansen, F H, Tjan-Heijnen, V C G, and Duijm, L E M

Published
2021

18. Nonradioactive surgical guidance with radiofrequency identification technology for locating nonpalpable breast lesions; Initial experiences of the RFID Localizer I Trial

Author

Researchgr. Systems Radiology, Onderzoek Beeld, Cancer, MS Radiologie, Christenhusz, A., Den Dekker, B., Van Dalen, T., Jongen, L., Van der Schaaf, M., Haken, B. Ten, Pijnappel, R., Dassen, A., Researchgr. Systems Radiology, Onderzoek Beeld, Cancer, MS Radiologie, Christenhusz, A., Den Dekker, B., Van Dalen, T., Jongen, L., Van der Schaaf, M., Haken, B. Ten, Pijnappel, R., and Dassen, A.

Published
2020

26. Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening : the RACER trial study design

Author

Neeter, L M F H, Houben, I P L, Nelemans, P J, Van Nijnatten, T J A, Pijnappel, R M, Frotscher, C, Osinga-de Jong, M, Sanders, F, Van Dalen, T, Raat, H P J, Essers, B A B, Wildberger, J E, Smidt, M L, Lobbes, M B I, Neeter, L M F H, Houben, I P L, Nelemans, P J, Van Nijnatten, T J A, Pijnappel, R M, Frotscher, C, Osinga-de Jong, M, Sanders, F, Van Dalen, T, Raat, H P J, Essers, B A B, Wildberger, J E, Smidt, M L, and Lobbes, M B I

Published
2019

27. Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening: the RACER trial study design

Author

MS Radiologie, Cancer, MS CGO, Neeter, L M F H, Houben, I P L, Nelemans, P J, Van Nijnatten, T J A, Pijnappel, R M, Frotscher, C, Osinga-de Jong, M, Sanders, F, Van Dalen, T, Raat, H P J, Essers, B A B, Wildberger, J E, Smidt, M L, Lobbes, M B I, MS Radiologie, Cancer, MS CGO, Neeter, L M F H, Houben, I P L, Nelemans, P J, Van Nijnatten, T J A, Pijnappel, R M, Frotscher, C, Osinga-de Jong, M, Sanders, F, Van Dalen, T, Raat, H P J, Essers, B A B, Wildberger, J E, Smidt, M L, and Lobbes, M B I

Published
2019

30. Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging

Author

Evans A, Trimboli R, Athanasiou A, Balleyguier C, Baltzer P, Bick U, Camps Herrero J, Clauser P, Colin C, Cornford E, Fallenberg E, Fuchsjaeger M, Gilbert F, Helbich T, Kinkel K, Heywang-Koebrunner S, Kuhl C, Mann R, Martincich L, Panizza P, Pediconi F, Pijnappel R, Pinker K, Zackrisson S, Forrai G, Sardanelli F, European Soc Breast Imaging EUSOBI, and Europa Donna European Breast Canc

Subjects
Breast cancer, BI-RADS, Automated whole breast ultrasound, Elastography, Colour-Doppler, Breast ultrasound (US)
Abstract

This article summarises the information that should be provided to women and referring physicians about breast ultrasound (US). After explaining the physical principles, technical procedure and safety of US, information is given about its ability to make a correct diagnosis, depending on the setting in which it is applied. The following definite indications for breast US in female subjects are proposed: palpable lump; axillary adenopathy; first diagnostic approach for clinical abnormalities under 40 and in pregnant or lactating women; suspicious abnormalities at mammography or magnetic resonance imaging (MRI); suspicious nipple discharge; recent nipple inversion; skin retraction; breast inflammation; abnormalities in the area of the surgical scar after breast conserving surgery or mastectomy; abnormalities in the presence of breast implants; screening high-risk women, especially when MRI is not performed; loco-regional staging of a known breast cancer, when MRI is not performed; guidance for percutaneous interventions (needle biopsy, pre-surgical localisation, fluid collection drainage); monitoring patients with breast cancer receiving neo-adjuvant therapy, when MRI is not performed. Possible indications such as supplemental screening after mammography for women aged 40-74 with dense breasts are also listed. Moreover, inappropriate indications include screening for breast cancer as a stand-alone alternative to mammography. The structure and organisation of the breast US report and of classification systems such as the BI-RADS and consequent management recommendations are illustrated. Information about additional or new US technologies (colour-Doppler, elastography, and automated whole breast US) is also provided. Finally, five frequently asked questions are answered. Teaching Points US is an established tool for suspected cancers at all ages and also the method of choice under 40. For US-visible suspicious lesions, US-guided biopsy is preferred, even for palpable findings. High-risk women can be screened with US, especially when MRI cannot be performed. Supplemental US increases cancer detection but also false positives, biopsy rate and follow-up exams. Breast US is inappropriate as a stand-alone screening method.

Published
2018

32. Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts

Author

de Lange, S. V., Bakker, M. F., Monninkhof, E. M., Peeters, P. H.M., de Koekkoek-Doll, P. K., Mann, R. M., Rutten, M. J.C.M., Bisschops, R. H.C., Veltman, J., Duvivier, K. M., Lobbes, M. B.I., de Koning, H. J., Karssemeijer, N., Pijnappel, R. M., Veldhuis, W. B., van Gils, C. H., de Lange, S. V., Bakker, M. F., Monninkhof, E. M., Peeters, P. H.M., de Koekkoek-Doll, P. K., Mann, R. M., Rutten, M. J.C.M., Bisschops, R. H.C., Veltman, J., Duvivier, K. M., Lobbes, M. B.I., de Koning, H. J., Karssemeijer, N., Pijnappel, R. M., Veldhuis, W. B., and van Gils, C. H.

Published
2018

34. Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts

Author

Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, MS Radiologie, Circulatory Health, de Lange, S. V., Bakker, M. F., Monninkhof, E. M., Peeters, P. H.M., de Koekkoek-Doll, P. K., Mann, R. M., Rutten, M. J.C.M., Bisschops, R. H.C., Veltman, J., Duvivier, K. M., Lobbes, M. B.I., de Koning, H. J., Karssemeijer, N., Pijnappel, R. M., Veldhuis, W. B., van Gils, C. H., Epi Kanker Team A, Cancer, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, MS Radiologie, Circulatory Health, de Lange, S. V., Bakker, M. F., Monninkhof, E. M., Peeters, P. H.M., de Koekkoek-Doll, P. K., Mann, R. M., Rutten, M. J.C.M., Bisschops, R. H.C., Veltman, J., Duvivier, K. M., Lobbes, M. B.I., de Koning, H. J., Karssemeijer, N., Pijnappel, R. M., Veldhuis, W. B., and van Gils, C. H.

Published
2018

35. Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012

Author

MS Radiologie, Cancer, van Maaren, M C, Lagendijk, M, Tilanus-Linthorst, M M A, de Munck, L, Pijnappel, R M, Schmidt, M K, Wesseling, J, Koppert, L B, Siesling, S, MS Radiologie, Cancer, van Maaren, M C, Lagendijk, M, Tilanus-Linthorst, M M A, de Munck, L, Pijnappel, R M, Schmidt, M K, Wesseling, J, Koppert, L B, and Siesling, S

Published
2018

36. Abstract OT3-07-01: Update of the randomized, non-inferiority LORD trial testing safety of active surveillance for women with screen-detected low risk ductal carcinoma in situ (EORTC-1401-BCG/BOOG 2014-04, DCIS)

Author

Wesseling, J, primary, Elshof, LE, additional, Tryfonidis, K, additional, Poncet, C, additional, Aalders, K, additional, van Leeuwen-Stok, E, additional, Skinner, V, additional, Loo, C, additional, Winter-Warnars, G, additional, Bleiker, E, additional, Retèl, V, additional, Pijnappel, R, additional, Bijker, N, additional, Rutgers, E, additional, and van Duijnhoven, F, additional

Published
2018
Full Text
View/download PDF

37. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment : a study protocol

Author

Charaghvandi, R K, van Asselen, B, Philippens, M E P, Verkooijen, H M, van Gils, C H, van Diest, P J, Pijnappel, R M, Hobbelink, M G G, Witkamp, A J, van Dalen, T, van der Wall, E, van Heijst, T C, Koelemij, R, van Vulpen, M, van den Bongard, H J G D, Charaghvandi, R K, van Asselen, B, Philippens, M E P, Verkooijen, H M, van Gils, C H, van Diest, P J, Pijnappel, R M, Hobbelink, M G G, Witkamp, A J, van Dalen, T, van der Wall, E, van Heijst, T C, Koelemij, R, van Vulpen, M, and van den Bongard, H J G D

Published
2017

38. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol

Author

Onderzoek Radiotherapie, Cancer, Klinische Fysica RT, Trialbureau Beeld, Circulatory Health, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, MS Radiologie, Arts-assistenten Nucleaire Geneesk., MS CGO, Other research (not in main researchprogram), Divisie Beeld & Oncologie, Fysica Radiotherapie Research, Radiotherapie, MS Radiotherapie, Charaghvandi, R K, van Asselen, B, Philippens, M E P, Verkooijen, H M, van Gils, C H, van Diest, P J, Pijnappel, R M, Hobbelink, M G G, Witkamp, A J, van Dalen, T, van der Wall, E, van Heijst, T C, Koelemij, R, van Vulpen, M, van den Bongard, H J G D, Onderzoek Radiotherapie, Cancer, Klinische Fysica RT, Trialbureau Beeld, Circulatory Health, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Pathologie, MS Radiologie, Arts-assistenten Nucleaire Geneesk., MS CGO, Other research (not in main researchprogram), Divisie Beeld & Oncologie, Fysica Radiotherapie Research, Radiotherapie, MS Radiotherapie, Charaghvandi, R K, van Asselen, B, Philippens, M E P, Verkooijen, H M, van Gils, C H, van Diest, P J, Pijnappel, R M, Hobbelink, M G G, Witkamp, A J, van Dalen, T, van der Wall, E, van Heijst, T C, Koelemij, R, van Vulpen, M, and van den Bongard, H J G D

Published
2017

39. Interval breast cancers have worse tumor characteristics and survival compared to screen-detected breast cancers

Author

de Munck, L., Siesling, S., Pijnappel, R. M., van der Vegt, B., de Bock, G. H., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Abstract

Background There is debate to what extend screen-detected cancers (SDC) differ in tumor characteristics and survival from tumors that are detected not trough screening. These can be divide into three groups. Firstly, tumors who manifest clinically in the period between two screens after a negative screening (interval cancers) within 12 months or, secondly, within 12-24 months. Thirdly, we identified tumors in patients with a positive screening, followed by a benign assessment in the hospital, who developed breast cancer 12-24 months after screening (IC-after-positive-screen). The aim of this study was to determine whether interval cancers and IC-after-positive-screen have worse tumor characteristics and survival compared to SDC. Regarding decision-making for more aggressive treatment, these data are essential. Methods All women (50-75) who underwent a screening by the Dutch National Screening Program, region North between 2004-2008 were selected and data were merged with the Netherlands Cancer Registry. SDC (diagnosed

Published
2016

40. Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol

Author

Charaghvandi, R. K., primary, van Asselen, B., additional, Philippens, M. E. P., additional, Verkooijen, H. M., additional, van Gils, C. H., additional, van Diest, P. J., additional, Pijnappel, R. M., additional, Hobbelink, M. G. G., additional, Witkamp, A. J., additional, van Dalen, T., additional, van der Wall, E., additional, van Heijst, T. C., additional, Koelemij, R., additional, van Vulpen, M., additional, and van den Bongard, H. J. G. D., additional

Published
2017
Full Text
View/download PDF

41. Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program : validation of results in a large multireader, multicase study

Author

Lalji, U C, Houben, I P L, Prevos, R, Gommers, S, van Goethem, M, Vanwetswinkel, S, Pijnappel, R, Steeman, R, Frotscher, C, Mok, W, Nelemans, P, Smidt, M L, Beets-Tan, R G, Wildberger, J E, Lobbes, M B I, Lalji, U C, Houben, I P L, Prevos, R, Gommers, S, van Goethem, M, Vanwetswinkel, S, Pijnappel, R, Steeman, R, Frotscher, C, Mok, W, Nelemans, P, Smidt, M L, Beets-Tan, R G, Wildberger, J E, and Lobbes, M B I

Published
2016

42. Contrast-enhanced spectral mammography in recalls from the Dutch breast cancer screening program: validation of results in a large multireader, multicase study

Author

MS Radiologie, Cancer, Lalji, U C, Houben, I P L, Prevos, R, Gommers, S, van Goethem, M, Vanwetswinkel, S, Pijnappel, R, Steeman, R, Frotscher, C, Mok, W, Nelemans, P, Smidt, M L, Beets-Tan, R G, Wildberger, J E, Lobbes, M B I, MS Radiologie, Cancer, Lalji, U C, Houben, I P L, Prevos, R, Gommers, S, van Goethem, M, Vanwetswinkel, S, Pijnappel, R, Steeman, R, Frotscher, C, Mok, W, Nelemans, P, Smidt, M L, Beets-Tan, R G, Wildberger, J E, and Lobbes, M B I

Published
2016

43. Prediction of positive resection margins in patients with non-palpable breast cancer

Author

Barentsz, M. W., Postma, E.L., van Dalen, T., van den Bosch, M.A.A.J., Miao, H., Gobardhan, P. D., van den Hout, L. E., Pijnappel, R. M., Witkamp, A. J., van Diest, P. J., van Hillegersberg, R., Verkooijen, H. M., Barentsz, M. W., Postma, E.L., van Dalen, T., van den Bosch, M.A.A.J., Miao, H., Gobardhan, P. D., van den Hout, L. E., Pijnappel, R. M., Witkamp, A. J., van Diest, P. J., van Hillegersberg, R., and Verkooijen, H. M.

Published
2015

44. Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed : An ideal prospective development study

Author

Barentsz, M. W., Verkooijen, H. M., Pijnappel, R. M., Fernandez, M. A., van Diest, P. J., van der Pol, C. C., Witkamp, A. J., Hobbelink, M. G G, Sever, A. R., van den Bosch, M. A A J, Barentsz, M. W., Verkooijen, H. M., Pijnappel, R. M., Fernandez, M. A., van Diest, P. J., van der Pol, C. C., Witkamp, A. J., Hobbelink, M. G G, Sever, A. R., and van den Bosch, M. A A J

Published
2015

45. Prediction of positive resection margins in patients with non-palpable breast cancer

Author

Onderzoek Beeld, Heelkunde Opleiding, Divisie Beeld & Oncologie, Circulatory Health, Cancer, MS Radiologie, MS CGO, Pathologie, Trialbureau Beeld, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Barentsz, M. W., Postma, E.L., van Dalen, T., van den Bosch, M.A.A.J., Miao, H., Gobardhan, P. D., van den Hout, L. E., Pijnappel, R. M., Witkamp, A. J., van Diest, P. J., van Hillegersberg, R., Verkooijen, H. M., Onderzoek Beeld, Heelkunde Opleiding, Divisie Beeld & Oncologie, Circulatory Health, Cancer, MS Radiologie, MS CGO, Pathologie, Trialbureau Beeld, Epi Kanker Team A, JC onderzoeksprogramma Kanker, Barentsz, M. W., Postma, E.L., van Dalen, T., van den Bosch, M.A.A.J., Miao, H., Gobardhan, P. D., van den Hout, L. E., Pijnappel, R. M., Witkamp, A. J., van Diest, P. J., van Hillegersberg, R., and Verkooijen, H. M.

Published
2015

46. Sentinel lymph node localization with contrast-enhanced ultrasound and an I-125 seed: An ideal prospective development study

Author

Pathologie, Cancer, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, MS Radiologie, MS CGO, Other research (not in main researchprogram), Arts-assistenten Nucleaire Geneesk., AIOS Psychiatrie, JC onderzoeksprogramma Kanker, Barentsz, M. W., Verkooijen, H. M., Pijnappel, R. M., Fernandez, M. A., van Diest, P. J., van der Pol, C. C., Witkamp, A. J., Hobbelink, M. G G, Sever, A. R., van den Bosch, M. A A J, Pathologie, Cancer, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, MS Radiologie, MS CGO, Other research (not in main researchprogram), Arts-assistenten Nucleaire Geneesk., AIOS Psychiatrie, JC onderzoeksprogramma Kanker, Barentsz, M. W., Verkooijen, H. M., Pijnappel, R. M., Fernandez, M. A., van Diest, P. J., van der Pol, C. C., Witkamp, A. J., Hobbelink, M. G G, Sever, A. R., and van den Bosch, M. A A J

Published
2015

48. Standalone computer-aided detection compared to radiologists' performance for the detection of mammographic masses

Author

Hupse, R., Samulski, M., Lobbes, M., Heeten, A. den, Imhof-Tas, M.W., Beijerinck, D., Pijnappel, R., Hitge-Boetes, C., Karssemeijer, N., Hupse, R., Samulski, M., Lobbes, M., Heeten, A. den, Imhof-Tas, M.W., Beijerinck, D., Pijnappel, R., Hitge-Boetes, C., and Karssemeijer, N.

Abstract

Item does not contain fulltext, OBJECTIVES: We developed a computer-aided detection (CAD) system aimed at decision support for detection of malignant masses and architectural distortions in mammograms. The effect of this system on radiologists' performance depends strongly on its standalone performance. The purpose of this study was to compare the standalone performance of this CAD system to that of radiologists. METHODS: In a retrospective study, nine certified screening radiologists and three residents read 200 digital screening mammograms without the use of CAD. Performances of the individual readers and of CAD were computed as the true-positive fraction (TPF) at a false-positive fraction of 0.05 and 0.2. Differences were analysed using an independent one-sample t-test. RESULTS: At a false-positive fraction of 0.05, the performance of CAD (TPF?=?0.487) was similar to that of the certified screening radiologists (TPF?=?0.518, P?=?0.17). At a false-positive fraction of 0.2, CAD performance (TPF?=?0.620) was significantly lower than the radiologist performance (TPF?=?0.736, P <0.001). Compared to the residents, CAD performance was similar for all false-positive fractions. CONCLUSIONS: The sensitivity of CAD at a high specificity was comparable to that of human readers. These results show potential for CAD to be used as an independent reader in breast cancer screening. KEY POINTS : � Computer-aided detection (CAD) systems are used to detect malignant masses in mammograms � Current CAD systems operate at low specificity to avoid perceptual oversight � A CAD system has been developed that operates at high specificity � The performance of the CAD system is approaching that of trained radiologists � CAD has the potential to be an independent reader in screening.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results